The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...

Bluish hands, known as peripheral cyanosis, can be a harmless response to cold but may signal poor circulation or serious ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...